Article Text

Download PDFPDF
Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin
  1. Si Xuan Koo1,
  2. Sock Hoai Chan2,
  3. Joanne Ngeow2
  1. 1Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
  2. 2National Cancer Centre Singapore, Singapore, Singapore
  1. Correspondence to Dr Joanne Ngeow, jongeow{at}


A Chinese man who had undergone a curative high anterior resection for sigmoid cancer was administrated XELOX (capecitabine and oxaliplatin) as postoperative adjuvant chemotherapy. He subsequently developed sinusoidal obstruction syndrome (SOS) that resolved on discontinuation of XELOX treatment. Genetic evaluation determined that he had the GSTT1-null and GSTM1-null genotype, known to be an independent risk factor for developing oxaliplatin-induced SOS.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.